Biological E reduces price of pentavalent vaccine for GAVI

The price reduction will allow GAVI,a non profit public private partnership that acts as a facilitator for distributing vaccines, to save $150 million in the next four years

shutterstock-365

A supply agreement with Hyderabad based Biological E has made the five-in-one shot available to GAVI for just $1.19 per dose, compared to the 2012 weighted average price of $2.17.This new, more cost-effective price provides the opportunity for the GAVI Alliance to pay up to US$ 150 million less over the next four years compared with using lowest cost alternative suppliers.

The contributions of vaccine companies from the developing world, especially India to allowing greater access to life saving vaccines have been acknowledged by stalwarts. "More affordable vaccines help us save and protect more children," said Bill Gates, co-chair of the Bill & Melinda Gates Foundation. "Today's announcement is a testimony to the vision of Biological E's Dr. Vijay K. Datla, who was committed to manufacturing vaccines at prices that make them one of the most cost-effective investments we can make in global health."

Mahima Datla, Managing Director of Biological E also added,"This partnership demonstrates the growing role of developing world manufacturers in the sustainable supply of effective, affordable vaccines. We are proud that our work to provide affordable prices for a variety of countries means life-saving vaccines can reach the most underprivileged children in the world."

UNICEF, an Alliance partner, managed the tender process for GAVI, which saw agreements made with Biological E, Crucell, GlaxoSmithKline, Serum Institute of India and new pentavalent supplier, LG Life Sciences of the Republic of Korea.

The GAVI Alliance was created in 2000 to accelerate the introduction of new vaccines so that all children, no matter where they live, have the same access to this life-saving technology. National governments, donors and vaccine suppliers must all play their part to ensure infants in the poorest countries are protected.The partnership aggregates donor funding, pools demand from countries, and works with suppliers to deliver lower and more accessible pricing. This reduces risk to supplies, enabling all partners to benefit and, most importantly, ensuring that the world can urgently reach all children with the vaccines they need.

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X